Cipla Ltd.

Cipla USA, Inc, a subsidiary of Cipla, has secured rights from Hyderabad-based MSN Laboratories to market and distribute colon cancer treatment drug Capecitabine in the US market. The company will be marketing the drug in strengths of 150 and 500 mg tablets. Its product is generic equivalent of Genentech's Xeloda.

Capecitabine tablets are indicated in patients with Dukes C colon cancer and for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. As per IQVIA (IMS Health), Xeloda and its generic equivalents had sales of around $178 million in the US for 12-month period ending June 2018.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.